Dermatologic toxicity of high doses of tiothepa in children. Case report

Hematopoietic stem cell transplantation (HSCT) is a treatment modality for a number of severe malignant and non-neoplastic diseases. Autologous hematopoietic stem cell transplantation (auto-HSCT) improves outcomes in patients with solid and hematological malignancies. Skin lesions at the auto-HSCT stage are quite common and represent an important diagnostic and therapeutic problem. The most significant causes of skin lesions in auto-HSCT are drug toxicity, infectious and viral lesions. Each of the complications can manifest itself to varying degrees as well as combine with others, having a significant negative on the patient’s condition, posing a threat to the patient’s life in severe cases.

1. Aliev TZ, Machneva EB, Sidorova NV, et al. Skin damage after the hematopoietic stem cell transplantation. Literature review. Pediatric Hematology/Oncology and Immunopathology. 2020;19(2):184–192. (In Russ). doi: https://doi.org/10.24287/1726-1708-2020-19-2-184-192]

2. Belysheva TS, Aliev TZ, Valiev TT, et al. Clinical Features of Cutaneous Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cells Transplantation in Children with Hemato-Oncological Diseases. Voprosy sovremennoi pediatrii — Current Pediatrics. 2020;19(6):500–508. (In Russ). doi: https://doi.org/10.15690/vsp.v19i6.2148]

3. Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3):524–529. doi: https://doi.org/10.1016/j.jaad.2008.05.018

4. Horn TD, Beveridge RA, Egorin MJ, et al. Observations and proposed mechanism of N,N′,N′′-triethyl-enethiophosphoramide (thiotepa)-induced hyperpigmenta-tion. Arch Dermatol. 1989;125(4):524–527.

5. Summary of Product Characteristics. Thiotepa. In: Electronic medicines compendium. Available online: https://www.medicines.org.uk/emc/product/12717/smpc#gref. Accessed on Marth 29, 2023.

6. Tepadina®, Thiotepa for injection, product monograph including patient medication information. Available online: https://methapharm.com/wp-content/uploads/2021/05/00056680-TepadinaPM-EN_June15-2020.pdf. Accessed on Marth 29, 2023.

7. Rosman IS, Lloyd BM, Hayashi RJ, et al. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol. 2008;58(4):575–578. doi: https://doi.org/10.1016/j.jaad.2007.12.037

8. Koppel RA, Boh EE. Cutaneous reactions to chemotherapeutic agents. Am J Med Sci. 2001;321(5):327–335. doi: https://doi.org/10.1097/00000441-200105000-00005

9. Beyer J, Grabbe J, Lenz K, et al. Cutaneous toxicity of high-dose carboplatin, etoposide and ifosfamide followed by autologous stem cell reinfusion. Bone Marrow Transplant. 1992;10(6):491–494.

10. Lucidarme N, Valteau-Couanet D, Oberlin O, et al. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors. Bone Marrow Transplant. 1998;22(6):535–540. doi: https://doi.org/10.1038/sj.bmt.1701395

11. Wise M, Maroon M, Fussell N. Cutaneous toxicity associated with tiotepa before autologous stem cell transplant. JAAD. 2010;62(3 Suppl 1):AB48. doi: https://doi.org/10.1016/j.jaad.2009.11.239

12. Van Schandevyl G, Bauters T. Thiotepa-induced cutaneous toxicity in pediatric patients: Case report and implementation of preventive care guidelines. J Oncol Pharm Pract. 2019;25(3):689–693. doi: https://doi.org/10.1177/1078155218796905

13. US Food and Drug Administration. Full prescribing information Tepadina. Reference ID: 4046754. Available online: www.accessdata.fda.gov/drugsatfda_docs/label/2017/208264s000lbl.pdf. Accessed on May 24, 2018.

14. Belysheva TS, Valiev TT, Aliev TZ. Dermatologicheskaya toksichnost’ i mukozity pri lechenii zlokachestvennykh opukholei u detei. In: Protivoopukholevaya lekarstvennaya terapiya: National guidelines. Gorbunova VA, Stenina MB, eds. Moscow.: GEOTAR-Media; 2022. pp. 686–692. (In Russ). doi: https://doi.org/10.33029/9704-6897-5-ATDT-2022-1-708

15. Balsat M, Pillet S, Tavernier E, et al. Human Herpesvirus 6 Infection after Autologous Stem Cell Transplantation: A Multicenter Prospective Study in Adult Patients. J Infect. 2019;79(1):36–42. doi: https://doi.org/10.1016/j.jinf.2019.05.001

16. Miura T, Kikuchi N, Ohtsuka M, Yamamoto T. Varicella in a patient with drug-induced hypersensitivity syndrome developed after autologous peripheral stem cell transplantation. Int J Dermatol. 2018;57(9):e71–e73. doi: https://doi.org/10.1111/ijd.14091